CAV1 and type 2 diabetes mellitus: In order to test this hypothesis, we set out to examine the impact of caveolae-disrupting agent mβCD and the effect of Cav-1 genetic deficiency on endothelium-dependent vasodilator function in patients and rodent models of T2D, both ex vivo and in vivo.